By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Juno Therapeutics 

307 Westlake Avenue North
Suite 300
Seattle  Washington    U.S.A.
Phone: 206-582-1600 Fax: n/a


SEARCH JOBS

Juno is a clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of breakthrough immunotherapies. With one of the largest ever Series A investments for a biotech startup, Juno will build on the foundation of novel immunotherapies to develop two distinct and complementary platforms – CARs and TCRs.

The CAR technology is designed to target cell surface antigens that are expressed on cancer cells. In addition, the high-affinity TCR technology can also detect alterations in intracellular proteins present in tumor cells. These treatments have the potential to reduce longer-term toxicities associated with chemotherapeutics. Our goal is to drive multiple product candidates in select hematologic and solid tumor cancers to FDA licensure. Each product candidate has the potential to treat a variety of high-risk cancers.

YEAR FOUNDED:

August 5, 2013

LEADERSHIP:

Founders: : Hans Bishop, Richard Klausner, and Robert Nelsen

CEO and Co-founder: Hans Bishop

JOBS:

Please click here for job opportunities.

CLINICAL TRIAL:

Please click here for clinical trial information.


FOLLOW JUNO:



Key Statistics


Email: Info@junotherapeutics.com
Ownership: Private

Web Site: Juno
Employees: n/a
Symbol: JUNO
 



Industry
Biotechnology






Company News
How Much Juno (JUNO) Spent on Its Failed CAR-T Drug 5/26/2017 6:27:28 AM
Juno (JUNO) Appoints Jay Flatley To Board Of Directors 5/23/2017 9:06:15 AM
Juno (JUNO) To Present Key Clinical Data Updates On JCAR017 And JCAR014 At The 2017 ASCO Annual Meeting 5/18/2017 8:37:51 AM
Juno (JUNO) Reports First Quarter 2017 Financial Results 5/5/2017 6:34:00 AM
Juno (JUNO) To Report First Quarter 2017 Financial Results On Thursday, May 4 4/28/2017 6:47:25 AM
Juno (JUNO) Appoints Rupert Vessey To Board Of Directors 4/19/2017 8:29:41 AM
Juno (JUNO) Taps Ex-Genentech (RHHBY) Scientist to Head Up R&D at New Bay Area Office 4/17/2017 5:34:41 AM
Celgene (CELG) Stocks Up on More Juno (JUNO) Stock After Failed Flagship Drug Trial 3/29/2017 6:48:39 AM
Juno (JUNO) Reports Fourth Quarter And 2016 Financial Results 3/2/2017 7:11:42 AM
Juno (JUNO) Finally Drops Problem CAR-T Drug That Caused Deaths 3/2/2017 5:25:09 AM
12345678910...
//-->